Drug-coated balloons are approved outside the United States, not only for the treatment of peripheral arteries but also for coronary arteries. This review describes the technological basics, the scenarios of clinical application, and the current available data from clinical trials for the different coronary indications.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11308150 | PMC |
| http://dx.doi.org/10.1016/j.jscai.2023.100625 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sirolimus coated balloon for the treatment of femoropopliteal lesions: the new kid on the block is getting older 'step by step'.
Cardiovasc Diagn Ther
December 2024
GRN Hospital Weinheim, Department of Cardiology, Vascular Medicine & Pneumology, Weinheim, Germany.
Superiority of coronary paclitaxel DCBs to limus DCBs in the late angiographic outcomes: the first meta-analysis showing the differences of coronary DCBs.
Cardiovasc Diagn Ther
December 2024
Department of Cardiology, Dokkyo Medical University Saitama Medical Center, Saitama, Japan.
Sirolimus-coated balloons for peripheral arterial disease: walking free into the future of endovascular treatment.
Cardiovasc Diagn Ther
December 2024
Department of Angiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Association of Post-procedure Ankle-Brachial Index with Outcomes Following Drug-Coated Balloon Angioplasty in Femoropopliteal Artery Disease.
Am J Cardiol
January 2025
Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
Endovascular treatment of femoropopliteal artery (FPA) disease with Drug-coated balloons (DCBs) may face complications such as arterial recoil, dissection, and residual stenosis. Angiography has limited accuracy for evaluating blood flow through revascularized target lesions. Thus, there is a need for post-procedure hemodynamic assessment in treated limbs.
View Article and Find Full Text PDFImpact of drug-coated balloon for vascular luminal dilatational remodeling after balloon angioplasty in intracranial atherosclerotic stenosis - a retrospective cohort study.
J Neurointerv Surg
January 2025
Department of Cerebrovascular Disease, Zhengzhou University People's Hospital, Henan Provincial People's Hospital; Henan Provincial Cerebrovascular Interventional Innovation Engineering Technology Research Center, Henan International Joint Laboratory of Cerebrovascular Disease, Zhengzhou, Henan, China
Objective: This study aimed to examine the effect of drug-coated balloons (DCBs) on vascular luminal dilatational remodeling (VLDR) following simple balloon angioplasty.
Methods: A retrospective cohort study was conducted using data from patients diagnosed with intracranial atherosclerotic stenosis (ICAS), who were treated exclusively with balloon angioplasty at Henan Provincial People's Hospital between June 2019 and April 2023. Inverse probability weighting (IPW) was used to create balanced cohorts of patients who underwent drug-coated balloon angioplasty (DCBA) and plain old balloon angioplasty (POBA).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!